{
    "organizations": [],
    "uuid": "97f53cf5a3f5b8632fd670bf3426e155a960480c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-indias-panacea-biotec-gets-eir-fro/brief-indias-panacea-biotec-gets-eir-from-u-s-fda-for-malpur-facility-idUSFWN1QR0EB",
    "ord_in_thread": 0,
    "title": "BRIEF-India's Panacea Biotec Gets EIR From U.S. FDA For Malpur Facility‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 9 (Reuters) - Panacea Biotec Ltd:\n* GETS EIR FROM U.S. FDA * GETS ESTABLISHMENT INSPECTION REPORT INDICATING FORMAL CLOSURE OF INSPECTION AT PHARMACEUTICAL FORMULATION FACILITY AT MALPUR\n* CO NOW ALLOWED TO CONTINUE SUPPLY OF ALL APPROVED DRUG PRODUCTS BY U.S. FDA INTO INTER-STATE COMMERCE ‍​ Source text - bit.ly/2FDumVW Further company coverage:\n ",
    "published": "2018-03-09T17:28:00.000+02:00",
    "crawled": "2018-03-10T20:06:03.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "panacea",
        "biotec",
        "ltd",
        "get",
        "eir",
        "fda",
        "get",
        "establishment",
        "inspection",
        "report",
        "indicating",
        "formal",
        "closure",
        "inspection",
        "pharmaceutical",
        "formulation",
        "facility",
        "malpur",
        "co",
        "allowed",
        "continue",
        "supply",
        "approved",
        "drug",
        "product",
        "fda",
        "commerce",
        "source",
        "text",
        "company",
        "coverage"
    ]
}